Fred Hirsch:
A KEYNOTE on PD-L1 as a predictive biomarker of immunotherapy response: a complex picture
Matthew Hatton:

Cardiac doses of radical radiotherapy impact survival in NSCLC: a real-world analysis
Martin Reck:
A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
Marina Garassino: